W. Paul Glezen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
W. Paul Glezen has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Claudia A. Kozinetz
Department of Pediatrics, Baylor College of Medicine, Houston
1 shared publication- Lone Simonsen
Roskilde University
1 shared publication Manjusha J. Gaglani
Department of Pediatrics, Section of Pediatric Infectious Diseases, Scott and White Memorial Hospital and Texas &cf1 University College of Medicine, Temple, Texas
1 shared publicationPedro A. Piedra
Department of Molecular Virology and Microbiology
1 shared publicationW Paul
From the Department of MVM, Baylor College of Medicine, Houston, TX
1 shared publication
Latest Publications
- Open Access
- 15 October 2011
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 204 (8) , 1151-1153
Broadening Indications for Maternal Influenza Vaccination
(See the article by Bloom-Feshbach et al, on pages 1157–64 .)
- 15 October 2011
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 204 (8) , 1151-1153
Open AccessBroadening Indications for Maternal Influenza Vaccination
(See the article by Bloom-Feshbach et al, on pages 1157–64 .)
- 1 February 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9767) , 698-700
Cell-culture-derived influenza vaccine production
- 1 February 2011
- Published by Elsevier in The Lancet
- Vol. 377 (9767) , 698-700
Cell-culture-derived influenza vaccine production
- 15 December 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (12) , 1380-1382
How did the 2008-2009 seasonal influenza vaccine affect the pandemic?
- 15 December 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 51 (12) , 1380-1382
How did the 2008-2009 seasonal influenza vaccine affect the pandemic?
- Open Access
- 1 December 2010
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (11) , 1626-1633
Direct and Indirect Effectiveness of Influenza Vaccination Delivered to Children at School Preceding an Epidemic Caused by 3 New Influenza Virus Variants
Background. Influenza is an uncontrolled epidemic disease that is vaccine preventable. New recommendations for universal immunization present a chall
- 1 December 2010
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 202 (11) , 1626-1633
Open AccessDirect and Indirect Effectiveness of Influenza Vaccination Delivered to Children at School Preceding an Epidemic Caused by 3 New Influenza Virus Variants
Background. Influenza is an uncontrolled epidemic disease that is vaccine preventable. New recommendations for universal immunization present a chall
- Open Access
- 1 September 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (5) , 757-758
Benefits of a universal influenza immunization program: more than the reduction in the use of antibiotics.
The Universal Influenza Immunization Program (UIIP) of the Province of Ontario was initiated in 2000. When the progress of the UIIP is considered, it is important to recognize that it was created by an act of the provincial legislative body without prior preparation by the public health and medical communities. Infrastructures for expanded vaccine delivery and mechanisms for evaluation of the program were not in place at the time of initiation. Therefore, the achievements of the program are remarkable, as illustrated by the report by Kwong et al. [1] in this issue of Clinical Infectious Diseases.
- 1 September 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 49 (5) , 757-758
Open AccessBenefits of a universal influenza immunization program: more than the reduction in the use of antibiotics.
The Universal Influenza Immunization Program (UIIP) of the Province of Ontario was initiated in 2000. When the progress of the UIIP is considered, it is important to recognize that it was created by an act of the provincial legislative body without prior preparation by the public health and medical communities. Infrastructures for expanded vaccine delivery and mechanisms for evaluation of the program were not in place at the time of initiation. Therefore, the achievements of the program are remarkable, as illustrated by the report by Kwong et al. [1] in this issue of Clinical Infectious Diseases.
- Open Access
- 11 December 2008
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (24) , 2579-2585
Prevention and Treatment of Seasonal Influenza
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.
- 11 December 2008
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 359 (24) , 2579-2585
Open AccessPrevention and Treatment of Seasonal Influenza
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations.
- 1 October 2008
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 27 (10) , S104-S109
Universal Influenza Vaccination and Live Attenuated Influenza Vaccination of Children
Influenza is an uncontrolled epidemic disease that is vaccine preventable. Each winter the peak of medically attended acute respiratory illness coincides with the peak of influenza virus activity. The anatomy of an urban influenza epidemic is presented highlighting the role of children in the spread of influenza. The efficacy and safety of the live attenuated influenza vaccine (LAIV) for children are documented and the indirect effectiveness (herd protection) of vaccinating schoolchildren is demonstrated. Children have the highest attack rates during influenza epidemics and the consequences of influenza virus infection can be severe regardless of the virus type—A(H1N1), A(H3N2), or B. Early in the epidemic, over one-half of the culture-positive illnesses will occur in school-aged children demonstrating their role in spreading the virus in the community. LAIV has been shown to be superior to inactivated vaccine for children and is safe even for children with mild intermittent asthma. One dose of LAIV is effective and gives almost immediate protection. LAIV administered by nasal spray is readily accepted by children. Several studies have demonstrated herd protection by immunizing schoolchildren. These studies have shown that immunizing schoolchildren is more efficient than vaccinating elderly and high-risk patients directly. Current recommendations for influenza vaccine give priority to more than 200 million persons in the United States, but vaccine coverage has not improved since 1997. Systematic delivery of influenza vaccine in school-based and workplace-based clinics would greatly enhance the control of epidemic influenza and help prepare for the next pandemic.
- 1 October 2008
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 27 (10) , S104-S109
Universal Influenza Vaccination and Live Attenuated Influenza Vaccination of Children
Influenza is an uncontrolled epidemic disease that is vaccine preventable. Each winter the peak of medically attended acute respiratory illness coincides with the peak of influenza virus activity. The anatomy of an urban influenza epidemic is presented highlighting the role of children in the spread of influenza. The efficacy and safety of the live attenuated influenza vaccine (LAIV) for children are documented and the indirect effectiveness (herd protection) of vaccinating schoolchildren is demonstrated. Children have the highest attack rates during influenza epidemics and the consequences of influenza virus infection can be severe regardless of the virus type—A(H1N1), A(H3N2), or B. Early in the epidemic, over one-half of the culture-positive illnesses will occur in school-aged children demonstrating their role in spreading the virus in the community. LAIV has been shown to be superior to inactivated vaccine for children and is safe even for children with mild intermittent asthma. One dose of LAIV is effective and gives almost immediate protection. LAIV administered by nasal spray is readily accepted by children. Several studies have demonstrated herd protection by immunizing schoolchildren. These studies have shown that immunizing schoolchildren is more efficient than vaccinating elderly and high-risk patients directly. Current recommendations for influenza vaccine give priority to more than 200 million persons in the United States, but vaccine coverage has not improved since 1997. Systematic delivery of influenza vaccine in school-based and workplace-based clinics would greatly enhance the control of epidemic influenza and help prepare for the next pandemic.
- 1 December 2006
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 118 (6) , 1199-1206
Asthma, influenza, and vaccination
- 1 December 2006
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 118 (6) , 1199-1206
Asthma, influenza, and vaccination
- 1 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 37 (4) , 237-243
Herd protection against influenza
- 1 December 2006
- Published by Elsevier in Journal of Clinical Virology
- Vol. 37 (4) , 237-243
Herd protection against influenza
- Open Access
- 20 December 2005
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 35 (2) , 352-353
Commentary: Benefits of influenza vaccine in US elderly—new studies raise questions
During the period from 1989 to 1997 the vaccination rate for elderly persons ≥65 years of age in the US increased from 30 to 67%. Despite this increase in coverage, mortality and hospitalization rates continued to increase rather than decline as would be expected if the vaccine were optimally efficacious. Currently over 50 000 deaths result from influenza virus infections each year in the US.1 The rate of hospitalizations owing to complications of influenza has increased steadily since 1979 and the average number for the last decade is almost 400 000 per year.2 About 85% of deaths and 63% of hospitalizations attributable to influenza occur in persons ≥65 years of age. About two-thirds of the US elderly have been vaccinated each year since 1997. Despite substantial vaccine coverage in the most vulnerable group, no effect on national all-cause excess mortality or hospitalizations has been evident—even after taking population aging and changing virus dominance patterns into account.3 Furthermore, observational studies of large cohorts have reported that elderly persons who elect to take the influenza vaccine were less likely to die or to be hospitalized during the influenza season than were unvaccinated elderly.4 Protection rates were estimated at 47% for all wintertime deaths and 22–27% for hospitalization. The investigators noted that the elderly who chose to be vaccinated had more co-morbidities, like diabetes or cardiopulmonary diseases, listed on their administrative data files and were, therefore, considered to be at greater risk for complications of influenza than their unvaccinated cohorts. The apparent 50% reduction in mortality is remarkable because the wintertime excess all-cause mortality that might be attributed to influenza was found to be 1,3 The finding that influenza vaccine protection in these observational studies exceeded any possible expectation requires some explanation.
- 20 December 2005
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 35 (2) , 352-353
Open AccessCommentary: Benefits of influenza vaccine in US elderly—new studies raise questions
During the period from 1989 to 1997 the vaccination rate for elderly persons ≥65 years of age in the US increased from 30 to 67%. Despite this increase in coverage, mortality and hospitalization rates continued to increase rather than decline as would be expected if the vaccine were optimally efficacious. Currently over 50 000 deaths result from influenza virus infections each year in the US.1 The rate of hospitalizations owing to complications of influenza has increased steadily since 1979 and the average number for the last decade is almost 400 000 per year.2 About 85% of deaths and 63% of hospitalizations attributable to influenza occur in persons ≥65 years of age. About two-thirds of the US elderly have been vaccinated each year since 1997. Despite substantial vaccine coverage in the most vulnerable group, no effect on national all-cause excess mortality or hospitalizations has been evident—even after taking population aging and changing virus dominance patterns into account.3 Furthermore, observational studies of large cohorts have reported that elderly persons who elect to take the influenza vaccine were less likely to die or to be hospitalized during the influenza season than were unvaccinated elderly.4 Protection rates were estimated at 47% for all wintertime deaths and 22–27% for hospitalization. The investigators noted that the elderly who chose to be vaccinated had more co-morbidities, like diabetes or cardiopulmonary diseases, listed on their administrative data files and were, therefore, considered to be at greater risk for complications of influenza than their unvaccinated cohorts. The apparent 50% reduction in mortality is remarkable because the wintertime excess all-cause mortality that might be attributed to influenza was found to be 1,3 The finding that influenza vaccine protection in these observational studies exceeded any possible expectation requires some explanation.